Medistem, Inc. engages in the development and commercialization of adult stem cell therapies in the United States. The company is developing endometrial regenerative cell (ERC), a universal donor stem cell product that promotes new blood vessel formation (angiogenesis), reduce inflammation, regulate immune system function, and augment tissue repair and healing. It is developing ERCs to treat a range of diseases, including ischemic conditions, cardiovascular and neurological diseases, kidney failure, liver failure, pulmonary diseases, and orphan disease indications, as well as autoimmune diseases, such as type 1 diabetes. The company was formerly known as Medistem Laboratories, Inc. and changed its name to Medistem, Inc. in August 2008. Medistem, Inc. is headquartered in San Diego, California.
March 12, 2015
RegMed Thursday: a lot of air coming out of trades and pricing
September 25, 2014
RegMed has been punished TOO much
September 15, 2014
RegMed, a slow start to September
August 25, 2014
RegMed CEOs are damned if they do or don’t
August 6, 2014
RegMed - Cytori (CYTX) is the talk of the airwaves
August 5, 2014
Lower open expected; could Cytori's (CYTX) clinical HOLD penalize the sector?
March 20, 2014
Weak open expected; RegMed alternates closes
March 18, 2014
RegMed has been testing support levels
March 17, 2014
What’s the “tell” for the rest of the week?
March 14, 2014
No GPS - a long, slow and uncertain road
35 companies, 1 interpreter!
Insight, foresight and recommendation
SOLD to Intrexon (NYSE: XON). MEDS stockholders will receive $0.27 in cash and $1.08 worth of XON’s common stock, based on the 20-day volume-weighted average price of the stock immediately prior to closing. MEDS platform has been saved; having NOT being able to raise capital – having been on a “thin” string for a while - it was the only “play or option” left!
goneMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors